MX2022011732A - Conjugados de farmacos y anticuerpos anti-ccr7. - Google Patents

Conjugados de farmacos y anticuerpos anti-ccr7.

Info

Publication number
MX2022011732A
MX2022011732A MX2022011732A MX2022011732A MX2022011732A MX 2022011732 A MX2022011732 A MX 2022011732A MX 2022011732 A MX2022011732 A MX 2022011732A MX 2022011732 A MX2022011732 A MX 2022011732A MX 2022011732 A MX2022011732 A MX 2022011732A
Authority
MX
Mexico
Prior art keywords
drug conjugates
antibody drug
antibodies
antigen binding
binding fragments
Prior art date
Application number
MX2022011732A
Other languages
English (en)
Inventor
Tetsuo Uno
Bernhard Hubert Geierstanger
Shailaja Kasibhatla
Mark Knuth
Steven Bender
Tracy Charlton
Anna Galkin
Scott Martin Glaser
Sabine Rottmann
Sarah Rue
Glen Spraggon
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2022011732A publication Critical patent/MX2022011732A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A61K39/39525—Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta solicitud describe anticuerpos anti-CCR7, sus fragmentos de unión a antígeno y conjugados de fármaco y anticuerpo de dichos anticuerpos o fragmentos de unión a antígeno. La invención también se refiere a métodos para tratar o prevenir el cáncer usando los anticuerpos, los fragmentos de unión a antígeno y los conjugados de fármaco y anticuerpo. En el presente documento también se describen métodos para producir los anticuerpos, los fragmentos de unión a antígeno y los conjugados de fármaco y anticuerpo, y métodos para usar los anticuerpos y los fragmentos de unión a antígeno como reactivos de diagnóstico.
MX2022011732A 2017-02-03 2019-07-31 Conjugados de farmacos y anticuerpos anti-ccr7. MX2022011732A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762454476P 2017-02-03 2017-02-03

Publications (1)

Publication Number Publication Date
MX2022011732A true MX2022011732A (es) 2022-10-13

Family

ID=61283268

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019009119A MX2019009119A (es) 2017-02-03 2018-02-01 Conjugados de farmacos y anticuerpos anti-ccr7.
MX2022011732A MX2022011732A (es) 2017-02-03 2019-07-31 Conjugados de farmacos y anticuerpos anti-ccr7.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019009119A MX2019009119A (es) 2017-02-03 2018-02-01 Conjugados de farmacos y anticuerpos anti-ccr7.

Country Status (27)

Country Link
US (2) US11634497B2 (es)
EP (1) EP3577139A1 (es)
JP (1) JP7312111B2 (es)
CN (1) CN110248963B (es)
AR (1) AR110920A1 (es)
AU (1) AU2018215701B2 (es)
BR (1) BR112019015950A2 (es)
CA (1) CA3049639A1 (es)
CL (2) CL2019002144A1 (es)
CO (1) CO2019008209A2 (es)
CR (1) CR20190346A (es)
CU (1) CU24648B1 (es)
EA (1) EA201991763A1 (es)
EC (1) ECSP19054235A (es)
IL (1) IL267834B2 (es)
JO (1) JOP20190187A1 (es)
MA (1) MA51778A (es)
MX (2) MX2019009119A (es)
MY (1) MY194997A (es)
PE (1) PE20191328A1 (es)
PH (1) PH12019501773A1 (es)
SA (1) SA519402358B1 (es)
SG (1) SG11201906229QA (es)
TW (2) TW202323292A (es)
UY (1) UY37591A (es)
WO (1) WO2018142322A1 (es)
ZA (1) ZA201904218B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015018899B1 (pt) * 2013-02-08 2023-09-26 Novartis Ag Imunoconjugados, composição farmacêutica, anticorpos igg modificados ou fragmentos de anticorpo modificados dos mesmos e seu método de produção, e célula hospedeira
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
KR102697394B1 (ko) 2017-02-28 2024-08-20 씨젠 인크. 컨쥬게이션을 위한 시스테인 변이된 항체
IL319265A (en) 2018-12-21 2025-04-01 Avidity Biosciences Inc Anti-transferrin receptor antibodies and their uses
KR20240052881A (ko) * 2018-12-21 2024-04-23 노파르티스 아게 Pmel17에 대한 항체 및 이의 접합체
KR20220092500A (ko) * 2019-10-09 2022-07-01 캐터펄트 테라퓨틱스 비.브이. 혈액 악성종양을 치료하기 위한 btk 억제제 및/또는 bcl2-억제제와의 조합 요법에서의 항-ccr7 항체의 용도
AU2020372522B2 (en) 2019-10-25 2024-08-15 WuXi Biologics Ireland Limited Novel anti-CD47 antibodies and uses thereof
AU2021237465A1 (en) 2020-03-19 2022-10-13 Avidity Biosciences, Inc. Compositions and methods of treating Facioscapulohumeral muscular dystrophy
IL296393B1 (en) 2020-03-27 2025-12-01 Avidity Biosciences Inc Compositions and methods of treating muscle dystrophy
US20230181756A1 (en) * 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
TW202216768A (zh) 2020-06-22 2022-05-01 美商恩格姆生物製藥公司 Ｌａｉｒ－１結合劑及其使用方法
BR112023001359A2 (pt) 2020-07-27 2023-02-14 Tuojie Biotech Shanghai Co Ltd Conjugado de anticorpo-fármaco anti-cd79b, método de preparação do mesmo e uso farmacêutico do mesmo
WO2022097065A2 (en) * 2020-11-06 2022-05-12 Novartis Ag ANTIBODY Fc VARIANTS
AU2022218137A1 (en) 2021-02-03 2023-08-24 Mozart Therapeutics, Inc. Binding agents and methods of using the same
BR112023022297A2 (pt) * 2021-04-26 2023-12-26 Memorial Hospital For Cancer And Allied Diseases Receptores quiméricos que alvejam adgre2 e/ou clec12a e usos dos mesmos
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
KR20240135622A (ko) 2022-01-26 2024-09-11 상하이 맙젠 바이오텍 리미티드 항CD79b 항체-약물 접합체의 약학적 조성물 및 이의 용도
KR102748862B1 (ko) * 2022-05-19 2025-01-02 국민대학교 산학협력단 Ccr7의 활성 조절 항체
CN121487754A (zh) 2023-07-25 2026-02-06 江苏恒瑞医药股份有限公司 靶向c-Met的抗体-药物偶联物及其医药用途
WO2025174274A1 (ru) * 2024-02-16 2025-08-21 Ярослав Леонидович КАМИНСКИЙ Производные индолнафталенацетамидов и их применение

Family Cites Families (188)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US633410A (en) 1898-09-22 1899-09-19 George A Ames Ice-cutter.
US2429001A (en) 1946-12-28 1947-10-14 Axel H Stone Artificial hand
US3720760A (en) 1968-09-06 1973-03-13 Pharmacia Ab Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
ATE37983T1 (de) 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
WO1991005548A1 (en) 1989-10-10 1991-05-02 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2071867A1 (en) 1989-11-06 1991-05-07 Edith Mathiowitz Method for producing protein microspheres
CA2109528A1 (en) 1991-05-01 1992-11-02 Gregory A. Prince A method for treating infectious respiratory diseases
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
DK0563475T3 (da) 1992-03-25 2000-09-18 Immunogen Inc Konjugater af cellebindende midler og derivater af CC-1065
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5759804A (en) 1992-11-17 1998-06-02 Icos Corporation Isolated nucleic acid encoding seven transmembrane receptors
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
CA2207961A1 (en) 1995-01-05 1996-07-11 Robert J. Levy Surface-modified nanoparticles and method of making and using same
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
AU710347B2 (en) 1995-08-31 1999-09-16 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
DK0885002T3 (da) 1996-03-04 2011-08-22 Penn State Res Found Materialer og fremgangsmåder til forøgelse af cellulær internalisering
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
CA2277801C (en) 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6043551A (en) 1997-09-30 2000-03-28 Intel Corporation Metal locking structures to prevent a passivation layer from delaminating
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
US6153441A (en) 1998-02-17 2000-11-28 Smithkline Beecham Corporation Methods of screening for agonists and antagonists for human CCR7 receptor and CKβ-9 ligand and interaction thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
CA2336139C (en) 1998-06-24 2008-10-14 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
CA2335105C (en) 1998-07-22 2010-05-11 Osprey Pharmaceuticals Limited Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
AU5459599A (en) 1998-08-17 2000-03-06 Schering Corporation Regulation of dendritic cell trafficking
EP2275447A1 (en) 1999-11-24 2011-01-19 Schering Corporation Methods of inhibiting metastasis
NZ517772A (en) 1999-11-24 2004-03-26 Immunogen Inc Cytotoxic agents comprising taxanes and their therapeutic use
US6949243B1 (en) 1999-11-24 2005-09-27 Schering Corporation Methods of inhibiting metastasis
EP1242438B1 (en) 1999-12-29 2006-11-08 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
WO2002010138A2 (en) 2000-08-01 2002-02-07 Schering Corporation Uses of mammalian genes and related reagents
US6411163B1 (en) 2000-08-14 2002-06-25 Intersil Americas Inc. Transconductance amplifier circuit
AU2002251913A1 (en) 2001-02-02 2002-08-19 Millennium Pharmaceuticals, Inc. Hybrid antibodies and uses thereof
WO2002067771A2 (en) 2001-02-28 2002-09-06 Protein Design Labs, Inc. Chemokine receptors and disease
US20020168358A1 (en) 2001-04-30 2002-11-14 Gladue Ronald P. Treatment of T-cell mediated diseases
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
DE60216606T2 (de) 2001-06-07 2007-04-05 Chemocentryx Inc., Mountain View Zellwanderungsassay
US7442512B2 (en) 2001-11-30 2008-10-28 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
EP1578777B1 (en) 2002-07-15 2008-11-26 The Trustees of Princeton University Iap binding compounds
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
WO2004104574A2 (en) 2003-05-23 2004-12-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 7 (ccr7)
ITRM20030386A1 (it) 2003-08-05 2005-02-06 Istituto Naz Per Le Malattie Infettive Lazz Metodo e test diagnostici basati sull'analisi citofluorimetrica dei linfociti t antigene-specifici.
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
EP1715882A4 (en) 2004-01-16 2009-04-08 Univ Michigan SMAC-PEPTIDOMIMETIKA AND ITS USES
US7932382B2 (en) 2004-01-16 2011-04-26 The Regents Of The University Of Michigan Conformationally constrained Smac mimetics and the uses thereof
AU2005228950B2 (en) 2004-03-23 2012-02-02 Genentech, Inc. Azabicyclo-octane inhibitors of IAP
RS52545B (sr) 2004-04-07 2013-04-30 Novartis Ag Inhibitori protein apoptoze (iap)
US7274964B2 (en) 2004-04-16 2007-09-25 Bal Seal Engineering Co., Inc. Use of an axial canted coil spring as an electrical contact to minimize resistivity variations under dynamic loads
NZ588799A (en) 2004-07-02 2012-06-29 Genentech Inc Inhibitors of iap
WO2006010118A2 (en) 2004-07-09 2006-01-26 The Regents Of The University Of Michigan Conformationally constrained smac mimetics and the uses thereof
EP2457895A1 (en) 2004-07-12 2012-05-30 Idun Pharmaceuticals, Inc. Tetrapeptide analogs
ES2475207T3 (es) 2004-07-15 2014-07-10 Tetralogic Pharmaceuticals Corporation Compuestos de unión a IAP
US20080112934A1 (en) 2004-11-24 2008-05-15 Rafick-Pierre Sekaly Methods To Identify, Prepare, And Use Naive T Cell Recent Thymic Emigrants
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
DK1836201T4 (da) 2004-12-20 2013-11-11 Genentech Inc Pyrrolidininhibitorer af IAP.
US20110166319A1 (en) 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
ES2503719T3 (es) 2005-02-11 2014-10-07 Immunogen, Inc. Procedimiento para preparar conjugados de anticuerpos y de maitansinoides
CN101171337A (zh) 2005-03-09 2008-04-30 得克萨斯大学体系董事会 与基因表达的体内成像相关的方法和组合物
ES2720160T3 (es) 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
EP1910828A4 (en) 2005-07-01 2012-03-14 Univ St Louis PHOSPHOSPECTIVE CHEMOKIN RECEPTOR ANTIBODIES
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
WO2007003216A1 (en) * 2005-07-06 2007-01-11 Universidad Autónoma de Madrid Anti-ccr7 receptor antibodies for the treatment of cancer
AU2006283726C1 (en) 2005-08-24 2015-05-07 Immunogen, Inc. Process for preparing maytansinoid antibody conjugates
AU2006287416A1 (en) 2005-09-07 2007-03-15 Medimmune, Llc Toxin conjugated Eph receptor antibodies
AU2006297126A1 (en) 2005-09-30 2007-04-12 Government Of The United States Of America, As Represented By The Secretary Methods and compositions for modulating immune tolerance
WO2007048022A2 (en) 2005-10-21 2007-04-26 Alexion Pharmaceuticals, Inc. Antibody-polypeptide fusion proteins and methods for producing and using same
WO2007055823A2 (en) 2005-10-28 2007-05-18 Multispan, Inc. Gpcr expressing cell lines and antibodies
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
EP2029522A2 (en) 2006-05-23 2009-03-04 V.B. Medicare Pvt. Ltd. Recovery of dimethylformamide and other solvents from process streams of manufacture of trichlorogalactosucrose
WO2008034076A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclophosphamide in combination with immune therapeutics
WO2008034074A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclosphosphamide in combination with anti-idiotypic vaccines
BRPI0720647A2 (pt) 2006-12-29 2014-01-14 Osprey Pharmaceuticals Usa Inc Processos de seleção e produção de toxinas modificadas, conjugados contendo toxinas modificadas e usos dos mesmos
TWI432212B (zh) 2007-04-30 2014-04-01 Genentech Inc Ｉａｐ抑制劑
JP5191537B2 (ja) 2007-06-18 2013-05-08 エム・エス・ディー・オス・ベー・フェー ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
CA2699202C (en) 2007-09-12 2016-09-27 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
EP2214675B1 (en) 2007-10-25 2013-11-20 Genentech, Inc. Process for making thienopyrimidine compounds
EP2073009A1 (en) 2007-12-19 2009-06-24 Cell Med Research GMBH Method for T, NK and NKT cells
EP2242773B1 (en) 2008-02-11 2017-06-14 Cure Tech Ltd. Monoclonal antibodies for tumor treatment
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
HUE034763T2 (en) 2008-04-30 2018-02-28 Immunogen Inc Crosslinkers and their use
WO2009139853A2 (en) 2008-05-14 2009-11-19 Kim, Eldar Human monoclonal antibodies against human chemokine receptor ccr7
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
RS54233B1 (sr) 2008-08-25 2015-12-31 Amplimmune Inc. Kompozicije pd-1 antagonista i postupci za njihovu primenu
EP2328920A2 (en) 2008-08-25 2011-06-08 Amplimmune, Inc. Targeted costimulatory polypeptides and methods of use to treat cancer
HUE065752T2 (hu) 2008-12-09 2024-06-28 Hoffmann La Roche Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
ES2629337T3 (es) 2009-02-09 2017-08-08 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos
US20120282654A1 (en) * 2009-04-29 2012-11-08 Schering Corporation Antibody purification
US9101559B2 (en) 2009-05-08 2015-08-11 New York University Leukemic cell CNS infiltration controlled by notch-induced chemotaxis
MX2011012794A (es) 2009-06-03 2012-05-08 Immunogen Inc Metodos de conjugacion.
WO2011005481A1 (en) 2009-06-22 2011-01-13 Medimmune, Llc ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
EP2272977A1 (en) 2009-07-08 2011-01-12 Universite Libre De Bruxelles Diagnostic method and kit for the detection of a lymphocytic variant of hypereosinophilic syndrome
US8276780B2 (en) 2009-11-18 2012-10-02 Snyder Industries, Inc. Fitting torque arm restraint
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
WO2011123903A1 (en) 2010-04-08 2011-10-13 Adelaide Research & Innovation Pty Ltd Chemokine receptor heteromultimers, compounds that bind thereto and uses thereof
AU2011309114B2 (en) 2010-09-28 2015-03-19 Nb Health Laboratory Co., Ltd. Antihuman CCR7 antibodies, hybridoma, nucleic acid, vector, cell, medicinal composition, and antibody-immobilized carrier
UY33827A (es) 2010-12-22 2012-07-31 Abbott Lab Proteínas de unión a media-inmunoglobulina y sus usos
US20120195900A1 (en) 2010-12-22 2012-08-02 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
US9670277B2 (en) 2011-02-24 2017-06-06 The Schepens Eye Reasearch Institute, Inc. Compositions and methods for treating inflammatory conditions of the ocular surface
ME03353B (me) 2011-03-29 2019-10-20 Immunogen Inc Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
BR112013025228A2 (pt) 2011-03-29 2018-09-25 Immunogen Inc processo para fabricar conjugados de homogeneidade aperfeçoada
WO2012172343A2 (en) 2011-06-13 2012-12-20 Ith Immune Therapy Holdings Treating primary sclerosing cholangitis
WO2012172337A2 (en) 2011-06-13 2012-12-20 Ith Immune Therapy Holdings Treating cardiovascular disease
EP2718313B1 (en) 2011-06-13 2017-05-17 TLA Targeted Immunotherapies AB Treating respiratory conditions
ES2613593T3 (es) 2011-06-13 2017-05-24 Ith Immune Therapy Holdings Ab Diagnóstico y tratamiento de enfermedad inflamatoria del intestino y síndrome del intestino irritable
WO2012172341A2 (en) 2011-06-13 2012-12-20 Ith Immune Therapy Holdings Treating cancer
RU2011130448A (ru) 2011-07-22 2013-01-27 Зао "Евроген" Методы и наборы для увеличения разнообразия т-клеток
SG190466A1 (en) 2011-11-18 2013-06-28 Agency Science Tech & Res Methods for diagnosis and/or prognosis of ovarian cancer
EP2814525A1 (en) 2012-02-13 2014-12-24 Cook Medical Technologies LLC Medical devices for collecting pathogenic cells
WO2013179174A1 (en) 2012-05-29 2013-12-05 Koninklijke Philips N.V. Lighting arrangement
MX2014014894A (es) 2012-06-04 2015-02-20 Irm Llc Metodos de marcado especifico del sitio y moleculas producidas mediante los mismos.
US20150344580A1 (en) 2012-06-05 2015-12-03 Eldar Kim Human Monoclonal Antibodies Against Human Chemokine Receptor CCR7
US20150307619A1 (en) 2012-12-13 2015-10-29 The Schepens Eye Research Institute, Inc. Use of C-C Chemokine Receptor Type 7 (CCR7) Inhibitors
WO2014124258A2 (en) 2013-02-08 2014-08-14 Irm Llc Specific sites for modifying antibodies to make immunoconjugates
BR112015018899B1 (pt) 2013-02-08 2023-09-26 Novartis Ag Imunoconjugados, composição farmacêutica, anticorpos igg modificados ou fragmentos de anticorpo modificados dos mesmos e seu método de produção, e célula hospedeira
WO2014134483A2 (en) * 2013-02-28 2014-09-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
EP2970985A1 (en) 2013-03-14 2016-01-20 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
CN105007950B (zh) 2013-03-15 2019-01-15 诺华股份有限公司 抗体药物缀合物
JP6469644B2 (ja) 2013-03-15 2019-02-13 アムジエン・インコーポレーテツド 抗ｃｃｒ７抗原結合タンパク質に関係する方法および組成物
US9739274B2 (en) 2013-03-15 2017-08-22 Integrated Designs, L.P. Pump system and method having a quick change motor drive
WO2015031698A1 (en) 2013-08-28 2015-03-05 Stem Centrx, Inc. Site-specific antibody conjugation methods and compositions
WO2015033137A1 (en) 2013-09-04 2015-03-12 Imperial Innovations Limited Biological methods and materials for use therein
GB201315748D0 (en) 2013-09-04 2013-10-16 Imp Innovations Ltd Biological methods and materials for use therein
GB2518221A (en) 2013-09-16 2015-03-18 Sergej Michailovic Kiprijanov Tetravalent antigen-binding protein molecule
GB2519786A (en) 2013-10-30 2015-05-06 Sergej Michailovic Kiprijanov Multivalent antigen-binding protein molecules
US9988420B2 (en) 2013-12-17 2018-06-05 Novartis Ag Cytotoxic peptides and conjugates thereof
ES2716685T3 (es) 2014-01-24 2019-06-14 Dana Farber Cancer Inst Inc Moléculas de anticuerpo para PD-1 y usos de las mismas
EA201691827A1 (ru) 2014-03-12 2017-01-30 Новартис Аг Конкретные участки для модификации антител с целью получения иммуноконъюгатов
WO2015158855A1 (en) 2014-04-16 2015-10-22 Genovie Ab Regulatory t-cells for use in the treatment of inflammatory disorders of the human gastrointestinal tract
HUE056023T2 (hu) * 2014-05-22 2022-01-28 Byondis Bv Kapcsolt drogok helyspecifikus konjugációja ellenanyagokhoz, és a kapott ADC-k
SG11201609462RA (en) 2014-06-13 2016-12-29 Novartis Ag Auristatin derivatives and conjugates thereof
GB201419185D0 (en) * 2014-10-28 2014-12-10 Adc Biotechnology Ltd Method of synthesising ADCs using affinity resin
TW201625692A (zh) 2014-11-14 2016-07-16 諾華公司 抗體藥物結合物
EP3234307B1 (en) * 2014-12-17 2019-11-20 National Oilwell DHT, L.P. Method of pressure testing a wellbore
WO2016179472A2 (en) 2015-05-07 2016-11-10 University Of Maryland, Baltimore Modulation of natural killer cell tolerance
US20190194315A1 (en) 2015-06-17 2019-06-27 Novartis Ag Antibody drug conjugates
JP6844864B2 (ja) 2015-08-10 2021-03-17 ペプマブ ビー．ヴィー．ＰｅｐＭａｂ Ｂ．Ｖ． ヒト化抗ｃｃｒ７受容体抗体
US10893342B2 (en) * 2016-02-01 2021-01-12 Telefonaktiebolaget Lm Ericsson (Publ) Reconfigurable optical modulator
JOP20190187A1 (ar) * 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7

Also Published As

Publication number Publication date
CR20190346A (es) 2019-09-13
EP3577139A1 (en) 2019-12-11
ECSP19054235A (es) 2019-08-30
IL267834B2 (en) 2024-01-01
ZA201904218B (en) 2024-07-31
UY37591A (es) 2018-08-31
MX2019009119A (es) 2019-11-21
MY194997A (en) 2022-12-30
BR112019015950A2 (pt) 2020-04-07
PE20191328A1 (es) 2019-09-24
AU2018215701A1 (en) 2019-07-18
AU2018215701B2 (en) 2021-04-22
AR110920A1 (es) 2019-05-15
MA51778A (fr) 2019-12-11
IL267834A (en) 2019-09-26
CU20190072A7 (es) 2020-03-04
US20240092918A1 (en) 2024-03-21
US20200216548A1 (en) 2020-07-09
CN110248963B (zh) 2023-12-26
CL2024001473A1 (es) 2024-11-08
PH12019501773A1 (en) 2020-06-29
SA519402358B1 (ar) 2023-11-27
CL2019002144A1 (es) 2019-10-11
RU2019126481A3 (es) 2021-07-08
CU24648B1 (es) 2023-02-13
CO2019008209A2 (es) 2019-09-09
IL267834B1 (en) 2023-09-01
US12180291B2 (en) 2024-12-31
WO2018142322A1 (en) 2018-08-09
JOP20190187A1 (ar) 2019-08-01
RU2019126481A (ru) 2021-03-03
CN110248963A (zh) 2019-09-17
CA3049639A1 (en) 2018-08-09
JP2020506703A (ja) 2020-03-05
TW201831510A (zh) 2018-09-01
JP7312111B2 (ja) 2023-07-20
SG11201906229QA (en) 2019-08-27
US11634497B2 (en) 2023-04-25
TW202323292A (zh) 2023-06-16
EA201991763A1 (ru) 2019-12-30
TWI839325B (zh) 2024-04-21

Similar Documents

Publication Publication Date Title
MX2022011732A (es) Conjugados de farmacos y anticuerpos anti-ccr7.
PH12017500890A1 (en) Antibody drug conjugates
ZA202308021B (en) Anti-ctla4 antibodies and methods of making and using the same
JOP20200078B1 (ar) أجسام مضادة خاصة بـ cd47 وpd-l1
PH12018501554A1 (en) Ror1 antibody compositions and related methods
ZA201708265B (en) Tigit-binding agents and uses thereof
MX2024007724A (es) Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
WO2018031490A3 (en) Anti-ox40 binding proteins
BR112017025080A2 (pt) composto conjugado de fármaco com anticorpo anti-cd123, composição conjugada de fármaco com anticorpo, método de tratamento de um paciente que tem um câncer que expressa cd123, composição farmacêutica, e, anticorpo intacto ou fragmento de ligação de antígeno
WO2018069871A3 (en) Anti-kras binding proteins
MX2024004299A (es) Anticuerpos anti-pmel17 y conjugados de los mismos.
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
PH12019500802A1 (en) Antibodies that bind zika virus envelope protein and uses thereof
PH12020550218A1 (en) MONOCLONAL ANTIBODY TO IL-5Ra
AU2018345715A8 (en) DNA monoclonal antibodies targeting CTLA-4 for the treatment and prevention of cancer